Anifrolumab clinical trials

Injectable anifrolumab for polymyositis or dermatomyositis

This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.

Study of anifrolumab for lupus patients not yet on strong treatments

This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

IV anifrolumab for active lupus in children

This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.

LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease

This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.

Anifrolumab in breastfeeding mothers with lupus

This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.

Study on pregnancy outcomes in lupus patients using anifrolumab

This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.

Anifrolumab pregnancy outcomes study

This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.

Anifrolumab and risk study for lupus patients

This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.

Real-world study of anifrolumab for active lupus

This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.

Study of anifrolumab for lupus patients needing treatment

This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.

Anifrolumab for Primary Antiphospholipid Syndrome

This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.

Anifrolumab pregnancy safety study

This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.

Lupus study tracking real-world results with anifrolumab

This study looks at how well anifrolumab works for people with lupus in everyday medical care, not just in a research lab. It may help you if your doctor has decided to prescribe anifrolumab for the first time.

Study of anifrolumab for lupus in routine care

This study follows people with lupus who are starting a new medication called anifrolumab (given as a shot under the skin) as part of their regular medical care. It aims to see how well the medicine works in everyday life.